Generex Biotechnology Announces Analyst Report by Ari Zoldan at Seeking Alpha
September 09, 2020 09:39 ET
|
Generex Biotechnology Corp.
Article Published on September 8, 2020: Title: “Generex Biotechnology's COVID-19 Vaccine Could Outperform Competition”To view the report, go to: https://seekingalpha.com/article/4373034 MIRAMAR,...
NuGenerex Immuno-Oncology Announces the Cancellation of Shareholder Conference Call Originally Scheduled for Today, Thursday, August 27, 2020
August 27, 2020 08:00 ET
|
Generex Biotechnology Corp.
MIRAMAR, Fla., Aug. 27, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO) today announced that it has cancelled the investor conference call originally scheduled to be held, Thursday, August...
Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday, August 26th, 2020 at 9:30 AM Eastern
August 26, 2020 09:15 ET
|
Generex Biotechnology Corp.
The NuGenHealth Software as a Service (SaaS) SystemRemote Patient Monitoring (RPM)Chronic Care Management (CCM) The access information for the investor conference call remains as follows: Direct...
Generex Biotechnology Announces New Updated Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
August 25, 2020 15:10 ET
|
Generex Biotechnology Corp.
The access information for the investor conference call remains as follows: Direct Toll / International – 1-(866) 831-8711Domestic US/Canada - 1-(203) 518-9883 Program Title: Generex Biotechnology...
Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
August 25, 2020 12:19 ET
|
Generex Biotechnology Corp.
The access information for the investor conference call is as follows: Direct Toll / International – 1-(866) 831-8711 Domestic US/Canada - 1-(203) 518-9883 Program Title: Generex Biotechnology...
Generex Biotechnology Updates Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
August 19, 2020 09:00 ET
|
Generex Biotechnology Corp.
Letter of Intent (LOI) signed with potential partners in China to develop the Ii-Key-SARS-CoV-2 vaccine for China with a proposed $5 million upfront payment upon contract signing and minimum of $400...
Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
August 18, 2020 13:17 ET
|
Generex Biotechnology Corp.
Bintai Kinden Corporation Berhad (www.bintai.com.my) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf RegionUpfront...
Generex Announces Signed Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
August 18, 2020 09:00 ET
|
Generex Biotechnology Corp.
Bintai Kinden Corporation Berhad (www.bintai.com.my) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf RegionUpfront...
Generex Biotechnology Announces Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
August 17, 2020 09:00 ET
|
Generex Biotechnology Corp.
$20 Million Memorandum of Understanding completed with an investor for a strategic upmarket transaction$10 Million financing proposal in the same MOU for the acquisition of infectious disease and...
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen® for Vascular Repair
August 13, 2020 09:30 ET
|
Generex Biotechnology Corp.
A Hybrid Approach for Vascular Control and Repair of an Expanding Iatrogenic Femoral Artery PseudoaneurysmJ. Gorecka, J.F Chen, S. Shah, A. Dardik, R.J Guzman, N. Nassiri, Journal of Vascular Surgery...